Bristol-Myers Squibb Co

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC.Anna Moneymaker | Getty ImagesA federal judge on Friday rejected AstraZeneca's legal challenge to Medicare's new power to negotiate the prices of certain costly prescription drugs with manufacturers.The decision is another win for the Biden administration in a bitter legal fight with the pharmaceutical industry over the constitutionality of those price…

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC.Anna Moneymaker | Getty ImagesA federal judge on Monday dismissed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations that challenged Medicare's new powers to negotiate prices for costly prescription medicines. The decision is an early win for the Biden administration as it grapples with a flurry of other legal…

Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024.Bill Clark | Cq-roll Call, Inc. | Getty ImagesSenators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb on U.S. drug prices at a hearing Thursday, as lawmakers on both sides of the aisle work to rein in high health-care costs for Americans. The push to cut drug prices is one of those rare hot-button…

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 1, 2024. Brendan McDermid | ReutersHere's how big of a surprise corporate profits have been this earnings season: the fourth-quarter is now shaping up to be the best of 2023.Despite ongoing macroeconomic concerns that have hampered demand and weighed on consumer sentiment, almost halfway into earnings season, profits are clearly coming in far better than anybody expected.Helping companies' bottom lines this round: easing input…

Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth. Here's what the company reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:Earnings per share: $1.70 adjusted vs. $1.53 expectedRevenue: $11.48 billion vs. $11.19 billion expectedBristol Myers, one of the world's largest pharmaceutical companies, booked $11.48 billion in revenue…

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com. Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.It took subpoena…

The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSEBig pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a so-called patent cliff.That refers to when a company's patents for one or more leading branded products expire, which opens the door for competitors to sell copycats of those drugs, often at a lower…

US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People's Action, protesting pharmaceutical companies' lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021.Saul Loeb | AFP | Getty ImagesThe CEOs of Merck and Johnson & Johnson have voluntarily agreed to testify at an upcoming Senate hearing on high drug prices in the U.S., Sen. Bernie Sanders…

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC.Anna Moneymaker | Getty ImagesU.S. patients and drugmakers will get a first glimpse of how much Medicare can negotiate down drug prices in 2024, setting the precedent for a controversial process that may affect what seniors pay for dozens of medications by the end of the decade. It could also be a pivotal year for the lawsuits that drugmakers – including…

Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share.Karuna's stock popped more than 47% on the news Friday morning, hitting around $317 a share. Bristol Myers Squibb shares rose more than 3%.The deal will help expand Bristol Myers' drug pipeline after competition from a generic offering caused demand for the company's blood cancer drug Revlimid to tumble in its third quarter.The boards of directors at both Bristol Myers and…